BR0109211A - Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa - Google Patents

Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa

Info

Publication number
BR0109211A
BR0109211A BR0109211-1A BR0109211A BR0109211A BR 0109211 A BR0109211 A BR 0109211A BR 0109211 A BR0109211 A BR 0109211A BR 0109211 A BR0109211 A BR 0109211A
Authority
BR
Brazil
Prior art keywords
treatment
retinal disorders
compounds useful
activity compounds
external retinal
Prior art date
Application number
BR0109211-1A
Other languages
English (en)
Inventor
Robert J Collier Jr
Michael A Kapin
Mark R Hellberg
Thomas R Dean
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BR0109211A publication Critical patent/BR0109211A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

"COMPOSTOS COM ATIVIDADE 5-HT~ 1A~ úTEIS PARA O TRATAMENTO DE DISTúRBIOS DA RETINA EXTERNA". São apresentados composições e métodos para tratamento de distúrbios da retina externa com compostos que têm atividade agonista 5-HT~ 1A~.
BR0109211-1A 2000-03-17 2001-02-23 Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa BR0109211A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19027900P 2000-03-17 2000-03-17
PCT/US2001/005700 WO2001070222A2 (en) 2000-03-17 2001-02-23 Compounds with 5-ht1a activity useful for treating disorders of the outer retina

Publications (1)

Publication Number Publication Date
BR0109211A true BR0109211A (pt) 2003-02-11

Family

ID=22700682

Family Applications (3)

Application Number Title Priority Date Filing Date
BR0109193-0A BR0109193A (pt) 2000-03-17 2001-02-20 Compostos com atividade agonista 5-ht2 e 5-ht1a para tratamento do glaucoma
BR0109211-1A BR0109211A (pt) 2000-03-17 2001-02-23 Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa
BR0109230-8A BR0109230A (pt) 2000-03-17 2001-02-23 Compostos com atividade 5-ht, úteis para controle da perda do campo visual

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0109193-0A BR0109193A (pt) 2000-03-17 2001-02-20 Compostos com atividade agonista 5-ht2 e 5-ht1a para tratamento do glaucoma

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0109230-8A BR0109230A (pt) 2000-03-17 2001-02-23 Compostos com atividade 5-ht, úteis para controle da perda do campo visual

Country Status (18)

Country Link
EP (3) EP1263434A1 (pt)
JP (5) JP2003527423A (pt)
KR (3) KR20030016239A (pt)
CN (2) CN1418100A (pt)
AR (1) AR028258A1 (pt)
AT (1) ATE247507T1 (pt)
AU (5) AU2001238552A1 (pt)
BR (3) BR0109193A (pt)
CA (3) CA2400637A1 (pt)
DE (1) DE60100625T2 (pt)
DK (1) DK1263504T3 (pt)
ES (1) ES2204848T3 (pt)
MX (3) MXPA02009071A (pt)
PL (1) PL203709B1 (pt)
PT (1) PT1263504E (pt)
TW (1) TWI268777B (pt)
WO (3) WO2001070223A1 (pt)
ZA (1) ZA200206350B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
MXPA02009071A (es) * 2000-03-17 2003-05-23 Alcon Inc Compuestos con actividad agonista de 5-ht 1a para tratar glaucoma..
TW593302B (en) * 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
EP1581209A4 (en) 2002-12-13 2009-03-11 Alcon Inc NEW BENZOPYRAN ANALOGUE AND ITS USE FOR THE TREATMENT OF GLAUKOM
JP2004262812A (ja) * 2003-02-28 2004-09-24 Rohto Pharmaceut Co Ltd 眼圧低下剤
JP4808612B2 (ja) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
WO2005053688A1 (en) 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
AR046890A1 (es) 2003-12-15 2005-12-28 Alcon Inc [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
EP1792629A4 (en) 2004-08-25 2010-08-25 Takeda Pharmaceutical MEANS FOR THE PREVENTION / TREATMENT OF STRESS-RELATED HARNINE INCONTINENCE AND PRECAUTIONARY METHOD FOR THIS
US7425572B2 (en) 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
WO2008117269A2 (en) 2007-03-28 2008-10-02 Atir Holding S.A. Heterotri cyciii c compounds as serotonergic and/or dopaminergic agents and uses thereof
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
EP2216023A4 (en) 2007-11-15 2013-03-13 Takeda Pharmaceutical CONDENSED PYRIDINE DERIVATIVE AND ITS USE
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
EP3421030A1 (en) 2009-11-09 2019-01-02 Allergan, Inc. Compositions and methods for stimulating hair growth
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
CA2901280A1 (en) 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
WO2020176597A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
JP7770673B2 (ja) 2019-02-27 2025-11-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脳障害を治療するためのアゼピノ－インドール及び他の複素環化合物
AU2022416279A1 (en) 2021-12-15 2024-07-25 Delix Therapeutics, Inc. Phenoxy and benzyloxy substituted psychoplastogens and uses thereof
PL4452267T3 (pl) * 2021-12-23 2025-06-23 Cilcare Dev Pochodne 4-fenylo-tetrahydropirydyny do leczenia chorób słuchu

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02262518A (ja) * 1989-04-03 1990-10-25 Kaken Pharmaceut Co Ltd 眼圧調整剤
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下１▼―ブロッカー点眼剤
TW270114B (pt) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
US5998467A (en) * 1995-10-25 1999-12-07 Mitsubishi Chemical Corporation Medicine for oculopathy
JP3958391B2 (ja) * 1995-10-25 2007-08-15 三菱化学株式会社 眼疾患用薬剤
AU4249297A (en) * 1996-10-31 1998-05-22 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
MXPA02009071A (es) * 2000-03-17 2003-05-23 Alcon Inc Compuestos con actividad agonista de 5-ht 1a para tratar glaucoma..

Also Published As

Publication number Publication date
AU2001238552A1 (en) 2001-10-03
ZA200206350B (en) 2003-08-08
EP1267878A2 (en) 2003-01-02
JP2003527423A (ja) 2003-09-16
MXPA02009071A (es) 2003-05-23
KR20030009390A (ko) 2003-01-29
CN1418100A (zh) 2003-05-14
DE60100625T2 (de) 2004-02-26
WO2001070230A3 (en) 2002-04-25
MXPA02009073A (es) 2003-03-12
WO2001070223A1 (en) 2001-09-27
JP2003527427A (ja) 2003-09-16
BR0109193A (pt) 2003-05-27
CN1418121A (zh) 2003-05-14
JP2003527422A (ja) 2003-09-16
CA2400639C (en) 2011-08-16
AU2001245310B2 (en) 2005-03-17
AU2005202600A1 (en) 2005-07-07
TWI268777B (en) 2006-12-21
AR028258A1 (es) 2003-04-30
EP1263504B1 (en) 2003-08-20
WO2001070230A2 (en) 2001-09-27
AU2005202600B2 (en) 2008-07-31
CA2399985A1 (en) 2001-09-27
AU2001239836A1 (en) 2001-10-03
WO2001070222A2 (en) 2001-09-27
KR20030016239A (ko) 2003-02-26
ATE247507T1 (de) 2003-09-15
EP1263504A2 (en) 2002-12-11
BR0109230A (pt) 2003-06-03
JP4789231B2 (ja) 2011-10-12
HK1051504A1 (en) 2003-08-08
AU4531001A (en) 2001-10-03
KR100749191B1 (ko) 2007-08-13
PT1263504E (pt) 2003-12-31
JP2011153158A (ja) 2011-08-11
JP2011037901A (ja) 2011-02-24
MXPA02009072A (es) 2003-03-12
CA2400637A1 (en) 2001-09-27
CA2400639A1 (en) 2001-09-27
CN1198605C (zh) 2005-04-27
PL203709B1 (pl) 2009-11-30
WO2001070222A3 (en) 2002-07-25
EP1263434A1 (en) 2002-12-11
DK1263504T3 (da) 2003-12-08
ES2204848T3 (es) 2004-05-01
DE60100625D1 (de) 2003-09-25
PL358306A1 (en) 2004-08-09
KR20020082885A (ko) 2002-10-31

Similar Documents

Publication Publication Date Title
BR0208373A (pt) Inibidores da tirosina cinase
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
BR0210241A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
BRPI0415395A (pt) composto, métodos para inibir a atividade da proteìna quinase e para tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase, e, composição
BR0014078A (pt) Inibidores de fator xa
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
BR0206639A (pt) Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
ES2282685T3 (es) Derivados de hidroxietilamina para el tratamiento de la enfermedad de alzheimer.
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
BR9914109A (pt) Composições antibióticas para tratamento dos olhos, ouvidos e nariz
EP1007556A4 (en) TROPONIN SUB-UNITS AND FRAGMENTS FOR USE AS INHIBITORS OF ANGIOGENESIS
PT1263504E (pt) Compostos com actividade 5-ht1a uteis para o tratamento de perturbacoes da retina externa
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
BR0312232A (pt) Inibidores de caspases e seus usos
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
BR9811099A (pt) Inibidores de urocinase
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
BR9813684A (pt) Processo para tratar o glaucoma glc1a, e, composição para controlar o glaucoma glc1a.
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
BR0315437A (pt) Composição para o tratamento dos cabelos, usos da mesma e método para o tratamento dos cabelos
BR0015392A (pt) Lipoxina a4 e seus análogos para o tratamento de olho ressecado
ATE234089T1 (de) Zubereitungen enthaltend sclareol und sclareolide zur behandlung mikrobieller infektionen

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 32 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]